This suggests a role for Rb-loss and hypoxia in NFκB signaling and that activation of the NFκB pathway in prostate cancer may signal a progression to metastatic, castrate-resistant or neuroendocrine disease. The gene discussed is RB1; the disease is prostate carcinoma.